Samsung Biologics
207940, KOSPI, Healthcare
- Prev. close
- ₩1,585,052
- Volume
- 40.8K
- Market cap
- ₩74T
- Major large cap
Why a candidate
Exp 41/100Lending balance
Unwinding805,398 sh
KRW 1.29T
New 7,826 sh, Returned 17,067 sh
Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.
As of 2026-08-26, FSC stock lending data
Company profile
Unqualified opinion삼성바이오로직스(주)
- CEO
- 임존종보 (Rim John Chongbo)
- Employees
- 5,455
- Average tenure
- 5.3 years
- Average pay per employee
- ₩114M
- Listed
- 2016-11-10
- Founded
- 2011-04-22
- Auditor
- 삼정회계법인
As filed 2026-08-26
Company siteToday's read
Samsung Biologics scores 41 out of 100 on today's InverseOne expectation ranking, 23 of 30 in the Korean large-cap universe. There is 24% of room left to its 52-week high. Today's move of +0.88% came with money flowing in, alongside the Healthcare sector. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.
Data basis: 2026-08-28, For reference only, not advice
Same-sector stocks, Healthcare
Talk about this stock
Today's talking points
- Borrowed shares are coming back. The lending balance is shrinking.
Three months out, which way do you see it?
Nobody has answered yet. Sign in to be the first.
These are answers picked by members, not investment advice.
These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.